Table 3.
Ordinal Outcomes and DOOR Estimates of Probability for Efficacy, Safety and Benefit-risk Outcomes in the First 30 Days of Treatmenta
| Outcome | Ceftazidime-Avibactam First | Colistin First | DOOR: IPTW-Adjusted Probability Estimate (95% CI) |
|||
|---|---|---|---|---|---|---|
| No. (%) | IPTW-Adjusted % (95% CI) | No. (%) | IPTW-adjusted % (95% CI) | IPTW-Adjusted Cumulative Difference for Colistin Minus Ceftazidime- Avibactam, % (95% CI) | ||
| Efficacy | ||||||
| disposition (n = 137) | n = 38 | n = 99 | 0.64 (.57– .71) | |||
| Hospital death | 3 (8) | 9 (3–20) | 33 (33) | 32 (23–41) | 23 (9–35) | |
| Alive in hospital or discharged not to home | 27 (71) | 72 (57–86) | 59 (60) | 61 (51–70) | 11 (−1 to 23) | |
| Discharged home | 8 (21) | 18 (8–31) | 7 (7) | 7 (3–13) | ||
| Safety | ||||||
| death and incident renal failure (n = 72) | n = 26 | n = 46 | 0.62 (.52–.72) | |||
| Hospital death | 2 (8) | 9 (3–24) | 12 (26) | 25 (13–38) | 16 (−2 to 32) | |
| Not observed to die, with incident renal failure | 1 (4) | 5 (3–19) | 6 (13) | 13 (4–24) | 24 (4–43) | |
| Not observed to die, without incident renal failure | 23 (88) | 86 (69–100) | 28 (61) | 62 (47–76) | ||
| Benefit-risk | ||||||
| analysis for death, discharge and incident renal failure (n = 72) | n = 26 | n = 46 | 0.64 (.53–.75) | |||
| Hospital death | 2 (8) | 9 (3–24) | 12 (26) | 25 (13–38) | 16 (−2 to 32) | |
| Alive in hospital or discharged not to home, incident renal failure | 1 (4) | 5 (3–19) | 5 (11) | 11 (3–21) | 22 (2–41) | |
| Alive in hospital or discharged not to home, no incident renal failure | 17 (65) | 65 (44–84) | 25 (54) | 56 (42–70) | 13 (−4 to 31) | |
| Discharged home | 6 (23) | 20 (7–38) | 4 (9) | 8 (2–16) | ||
Abbreviations: CI, confidence interval; DOOR, desirability of outcome ranking; IPTW, inverse probability of treatment weighting.
aThe DOOR estimates represent the probability that a randomly chosen patient from the study population has a more desirable outcome when starting ceftazidime-avibactam treatment than when starting colistin treatment.